From: The prognostic value of neuromedin U in patients with hepatocellular carcinoma
Clinical parameters | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Sex (male vs. female) | 0.914 | 0.560–1.492 | 0.720 | |||
Age (yrs) (≤60 vs. >60) | 1.092 | 0.765–1.558 | 0.630 | |||
HCC family history (yes vs. no) | 1.218 | 0.642–2.309 | 0.546 | |||
HBsAg (positive vs. negative) | 0.703 | 0.425–1.162 | 0.169 | |||
Cirrhosis (yes vs. no) | 0.916 | 0.635–1.320 | 0.636 | |||
Tumor number (single vs. multiple) | 2.163 | 1.569–2.981 | <0.001 | |||
Tumor size (cm) (≤5 vs. >5) | 2.355 | 1.670–3.320 | <0.001 | 1.551 | 1.065–2.258 | 0.022 |
Major vascular invasion (yes vs. no) | 2.510 | 1.743–3.617 | <0.001 | |||
Edmondson grade (I + II vs. III + IV) | 1.584 | 1.118–2.244 | 0.010 | 1.514 | 1.067–2.149 | 0.020 |
TNM stage (I + II vs. III + IV) | 3.077 | 2.240–4.225 | <0.001 | 2.484 | 1.767–3.494 | <0.001 |
Child-Pugh class (A vs. B) | 1.846 | 1.112–3.063 | 0.018 | 1.789 | 1.064–3.008 | 0.028 |
PLT count (×109) (≥100 vs. <100) | 2.623 | 1.338–5.141 | 0.005 | |||
TBIL (μmol/L) (<34.2 vs. ≥34.2) | 1.373 | 0.819–2.301 | 0.229 | |||
ALT (U/L) (≤40 vs. >40) | 1.281 | 0.867–1.894 | 0.214 | |||
AST (U/L) (≤37 vs. >37) | 2.328 | 1.643–3.299 | <0.001 | 1.775 | 1.225–2.572 | 0.002 |
AFP (ug/L) (≤20 vs. >20) | 1.218 | 0.850–1.744 | 0.282 | |||
NMU peri-tumor (low vs. high group) | 1.374 | 1.012–1.865 | 0.041 | |||
NMU intra-tumor (low vs. high group) | 1.179 | 0.867–1.604 | 0.294 |